[UMW] QoQ TTM Result on 30-Jun-2014 [#2]

Announcement Date
27-Aug-2014
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2014
Quarter
30-Jun-2014 [#2]
Profit Trend
QoQ- -16.3%
YoY- -45.16%
Quarter Report
View:
Show?
TTM Result
31/03/15 31/12/14 30/09/14 30/06/14 31/03/14 31/12/13 30/09/13 CAGR
Revenue 14,589,458 14,932,490 14,889,101 14,643,216 14,175,569 13,951,460 14,365,535 1.03%
PBT 1,462,098 1,621,460 1,645,845 1,461,215 1,482,349 1,435,673 1,592,534 -5.54%
Tax -405,176 -408,455 -402,003 -368,098 -341,212 -351,461 -351,525 9.94%
NP 1,056,922 1,213,005 1,243,842 1,093,117 1,141,137 1,084,212 1,241,009 -10.16%
-
NP to SH 581,579 651,970 655,324 559,780 668,807 652,926 822,995 -20.68%
-
Tax Rate 27.71% 25.19% 24.43% 25.19% 23.02% 24.48% 22.07% -
Total Cost 13,532,536 13,719,485 13,645,259 13,550,099 13,034,432 12,867,248 13,124,526 2.06%
-
Net Worth 6,602,729 6,580,415 6,643,970 6,542,212 6,415,452 6,290,328 5,025,299 19.98%
Dividend
31/03/15 31/12/14 30/09/14 30/06/14 31/03/14 31/12/13 30/09/13 CAGR
Div 479,000 479,000 397,219 397,219 397,219 397,219 584,146 -12.40%
Div Payout % 82.36% 73.47% 60.61% 70.96% 59.39% 60.84% 70.98% -
Equity
31/03/15 31/12/14 30/09/14 30/06/14 31/03/14 31/12/13 30/09/13 CAGR
Net Worth 6,602,729 6,580,415 6,643,970 6,542,212 6,415,452 6,290,328 5,025,299 19.98%
NOSH 1,168,293 1,168,293 1,168,293 1,168,293 1,168,293 1,168,293 1,168,293 0.00%
Ratio Analysis
31/03/15 31/12/14 30/09/14 30/06/14 31/03/14 31/12/13 30/09/13 CAGR
NP Margin 7.24% 8.12% 8.35% 7.47% 8.05% 7.77% 8.64% -
ROE 8.81% 9.91% 9.86% 8.56% 10.42% 10.38% 16.38% -
Per Share
31/03/15 31/12/14 30/09/14 30/06/14 31/03/14 31/12/13 30/09/13 CAGR
RPS 1,248.78 1,278.15 1,274.43 1,253.38 1,213.36 1,194.17 1,229.62 1.03%
EPS 49.78 55.81 56.09 47.91 57.25 55.89 70.44 -20.67%
DPS 41.00 41.00 34.00 34.00 34.00 34.00 50.00 -12.40%
NAPS 5.6516 5.6325 5.6869 5.5998 5.4913 5.3842 4.3014 19.98%
Adjusted Per Share Value based on latest NOSH - 1,168,293
31/03/15 31/12/14 30/09/14 30/06/14 31/03/14 31/12/13 30/09/13 CAGR
RPS 1,248.78 1,278.15 1,274.43 1,253.38 1,213.36 1,194.17 1,229.62 1.03%
EPS 49.78 55.81 56.09 47.91 57.25 55.89 70.44 -20.67%
DPS 41.00 41.00 34.00 34.00 34.00 34.00 50.00 -12.40%
NAPS 5.6516 5.6325 5.6869 5.5998 5.4913 5.3842 4.3014 19.98%
Price Multiplier on Financial Quarter End Date
31/03/15 31/12/14 30/09/14 30/06/14 31/03/14 31/12/13 30/09/13 CAGR
Date 31/03/15 31/12/14 30/09/14 30/06/14 31/03/14 31/12/13 30/09/13 -
Price 10.84 10.96 12.26 10.92 10.98 12.06 11.82 -
P/RPS 0.87 0.86 0.96 0.87 0.90 1.01 0.96 -6.35%
P/EPS 21.78 19.64 21.86 22.79 19.18 21.58 16.78 19.00%
EY 4.59 5.09 4.58 4.39 5.21 4.63 5.96 -15.99%
DY 3.78 3.74 2.77 3.11 3.10 2.82 4.23 -7.23%
P/NAPS 1.92 1.95 2.16 1.95 2.00 2.24 2.75 -21.31%
Price Multiplier on Announcement Date
31/03/15 31/12/14 30/09/14 30/06/14 31/03/14 31/12/13 30/09/13 CAGR
Date 26/05/15 26/02/15 26/11/14 27/08/14 23/05/14 26/02/14 21/11/13 -
Price 10.70 11.04 11.30 12.28 10.78 11.94 12.62 -
P/RPS 0.86 0.86 0.89 0.98 0.89 1.00 1.03 -11.34%
P/EPS 21.49 19.78 20.15 25.63 18.83 21.36 17.91 12.92%
EY 4.65 5.05 4.96 3.90 5.31 4.68 5.58 -11.45%
DY 3.83 3.71 3.01 2.77 3.15 2.85 3.96 -2.20%
P/NAPS 1.89 1.96 1.99 2.19 1.96 2.22 2.93 -25.36%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ & YoY figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment